DCXR-DT

Across TCGA pan-cancer cohorts, DCXR-DT RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of DCXR-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DCXR-DT RNA is repressed in tumor relative to normal tissue. In most cancer types DCXR-DT is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and THCA are the cancer types where DCXR-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DCXR-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−1.305	<.001	12	view →
KIRP	All	IV	−1.570	<.001	11	view →
THCA	Male	III,IV	−0.761	<.001	10	view →
COAD	All	All	+0.363	<.001	8	view →
KICH	Male	All	−1.249	<.001	7	view →
CHOL	Male	All	−2.980	<.001	5	view →
BRCA	Female	All	−0.261	<.001	4	view →
HNSC	Female	All	−0.330	.006	3	view →
LIHC	Female	All	−1.000	.006	2	view →
ESCA	All	All	−0.468	.013	2	view →
PRAD	All	All	+0.335	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

DCXR-DT–KIRC

Open the KIRC breakdown →